- Home
- CLNN vs BRNS Comparison
CLNN vs BRNS Comparison
Compare CLNN & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- BRNS
- Stock Information
- Founded
- CLNN 2012
- BRNS 2016
- Country
- CLNN United States
- BRNS United Kingdom
- Employees
- CLNN N/A
- BRNS N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- CLNN Health Care
- BRNS Health Care
- Exchange
- CLNN Nasdaq
- BRNS Nasdaq
- Market Cap
- CLNN 57.9M
- BRNS 48.3M
- IPO Year
- CLNN N/A
- BRNS 2021
- Fundamental
- Price
- CLNN $6.33
- BRNS $1.05
- Analyst Decision
- CLNN Strong Buy
- BRNS Strong Buy
- Analyst Count
- CLNN 6
- BRNS 1
- Target Price
- CLNN $32.67
- BRNS $3.00
- AVG Volume (30 Days)
- CLNN 122.8K
- BRNS 41.2K
- Earning Date
- CLNN 11-12-2025
- BRNS 11-05-2025
- Dividend Yield
- CLNN N/A
- BRNS N/A
- EPS Growth
- CLNN N/A
- BRNS N/A
- EPS
- CLNN N/A
- BRNS N/A
- Revenue
- CLNN $286,000.00
- BRNS $14,969,000.00
- Revenue This Year
- CLNN N/A
- BRNS N/A
- Revenue Next Year
- CLNN $2,178.18
- BRNS N/A
- P/E Ratio
- CLNN N/A
- BRNS N/A
- Revenue Growth
- CLNN N/A
- BRNS 1766.46
- 52 Week Low
- CLNN $2.28
- BRNS $0.64
- 52 Week High
- CLNN $7.10
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- CLNN 54.60
- BRNS 40.11
- Support Level
- CLNN N/A
- BRNS $1.08
- Resistance Level
- CLNN $6.71
- BRNS $1.20
- Average True Range (ATR)
- CLNN 0.53
- BRNS 0.09
- MACD
- CLNN -0.25
- BRNS -0.01
- Stochastic Oscillator
- CLNN 89.15
- BRNS 3.23
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.